A. Flacco

发表

Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.

L. Crinò, V. Ludovini, G. Servillo, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

L. Crinò, M. Tonato, I. Floriani, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Corrigendum to "Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology" (Biotechnol Adv 30 (2012) 142-153)

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2013 .

Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2012, Biotechnology advances.

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

M. Varella‐Garcia, L. Crinò, R. Chiari, 2013, Cancer Chemotherapy and Pharmacology.

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

L. Crinò, R. Chiari, C. Bennati, 2014, Clinical lung cancer.

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations

L. Crinò, F. Bianconi, R. Chiari, 2012, Cancer Chemotherapy and Pharmacology.

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung Cancer

M. Varella‐Garcia, L. Crinò, V. Ludovini, 2015, American journal of clinical oncology.

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

W. Franklin, M. Varella‐Garcia, R. Doebele, 2010, Clinical Cancer Research.

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients

L. Crinò, V. Ludovini, F. Bianconi, 2014, American journal of clinical oncology.

HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response

L. Crinò, V. Ludovini, M. Colozza, 2008 .

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

W. Franklin, R. Doebele, L. Crinò, 2010, Clinical Cancer Research.